Repare Therapeutics Statistics
Share Statistics
Repare Therapeutics has 42.89M
shares outstanding. The number of shares has increased by 0.15%
in one year.
| Shares Outstanding | 42.89M |
| Shares Change (YoY) | 0.15% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 72.15% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 10,057 |
| FTD / Avg. Volume | 3.24% |
Short Selling Information
The latest short interest is 694.21K, so 1.63% of the outstanding
shares have been sold short.
| Short Interest | 694.21K |
| Short % of Shares Out | 1.63% |
| Short % of Float | 2.7% |
| Short Ratio (days to cover) | 1.36 |
Valuation Ratios
The PE ratio is -0.66 and the forward
PE ratio is -1.05.
Repare Therapeutics's PEG ratio is
0.06.
| PE Ratio | -0.66 |
| Forward PE | -1.05 |
| PS Ratio | 1.04 |
| Forward PS | 0.4 |
| PB Ratio | 0.37 |
| P/FCF Ratio | -0.73 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Repare Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.77,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.77 |
| Quick Ratio | 6.77 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $414,550.39 |
| Profits Per Employee | $-656,503.88 |
| Employee Count | 129 |
| Asset Turnover | 0.3 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.44M |
| Effective Tax Rate | -1.73% |
Stock Price Statistics
The stock price has increased by -62.64% in the
last 52 weeks. The beta is 0.84, so Repare Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -62.64% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 2.26 |
| Relative Strength Index (RSI) | 59.23 |
| Average Volume (20 Days) | 310,088 |
Income Statement
In the last 12 months, Repare Therapeutics had revenue of 53.48M
and earned -84.69M
in profits. Earnings per share was -2.
| Revenue | 53.48M |
| Gross Profit | 51.56M |
| Operating Income | -93.52M |
| Net Income | -84.69M |
| EBITDA | -93.52M |
| EBIT | -92.14M |
| Earnings Per Share (EPS) | -2 |
Full Income StatementBalance Sheet
The company has 84.72M in cash and 1.93M in
debt, giving a net cash position of 82.78M.
| Cash & Cash Equivalents | 84.72M |
| Total Debt | 1.93M |
| Net Cash | 82.78M |
| Retained Earnings | -417.8M |
| Total Assets | 176.51M |
| Working Capital | 145.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -76.44M
and capital expenditures 0, giving a free cash flow of -76.44M.
| Operating Cash Flow | -76.44M |
| Capital Expenditures | n/a |
| Free Cash Flow | -76.44M |
| FCF Per Share | -1.8 |
Full Cash Flow StatementMargins
Gross margin is 96.41%, with operating and profit margins of -174.88% and -158.37%.
| Gross Margin | 96.41% |
| Operating Margin | -174.88% |
| Pretax Margin | -155.67% |
| Profit Margin | -158.37% |
| EBITDA Margin | -174.88% |
| EBIT Margin | -174.88% |
| FCF Margin | -142.95% |
